Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (2895)	7/28/1999 1:26:00 AM
From: Katz R Us	Respond to of 4140

Amen, BARRY!!!!!!!!!!!!!! B.

To: BARRY ALLEN who wrote (2895)	7/28/1999 9:04:00 AM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4140

NEVER SAY NEVER!!! Wednesday July 28 2:40 AM ET FDA Approves Flu Inhalant Drug By PAUL RECER AP Science Writer WASHINGTON (AP) - Ignoring the recommendation of its own advisory panel, the Food and Drug Administration approved an inhalant drug for the treatment of simple influenza. Studies show the drug, to be marketed under the name Relenza, can reduce the duration of flu symptoms by up to 36 hours, but critics said the benefit does not justify approval. An FDA advisory panel voted 13-4 in February against recommending approval of Relenza, saying the drug helped flu sufferers only slightly. The panel requested more studies, particularly among people in nursing homes and the elderly. Dr. Heidi M. Jolson, director of the FDA's antiviral drug product division, said approving a drug against the recommendation of an advisory committee ''doesn't happen commonly'' but Relenza adds a new weapon to the very limited flu-fighting arsenal. She said the need for some therapy against flu was a strong element in the decision. ''Influenza is an important public health problem, and this will provide another option for treatment,'' she said. Jolson said that since the advisory committee vote last February, the drug manufacturer, GlaxoWellcome Inc., has provided information to answer many of the questions raised during the panel's hearing. ''We felt we had sufficiently addressed the concerns that the advisory committee had brought up,'' Jolson said. dailynews.yahoo.com

To: BARRY ALLEN who wrote (2895)	7/28/1999 10:28:00 AM
From: Andrew G.	Respond to of 4140

Excellent post, Barry. SNRS only $634M below value since hitting it's high of $20 3/8 this month. I think we have a tad more to go on the upside, wouldn't you say? Although it may seem like a bit of a run-up today, consider how fast it dropped on shear panic. We could easily see a steep incline in the other direction if the FDA takes a similar stand to the one they took with the Relenza press release today. Best wishes to all. SNRS is not a safe short below $20 IMO